the aid library

LIST OPTIONS

Filter

13728

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (165)

View PDF (165)

Tool for the accreditation of research ethics committees

Pan American Health Organization PAHO (2023) C_WHO

The ethical governance of research assumes the existence of a national entity (or subnational if applicable, according to the constitution of a country) in charge of supervising the research ethics committees (RECs) that review and monitor research with human beings. This supervision includes the ac... more

Download (228)

View PDF (301)

Clinical management of diphtheria: guideline

World Health Organization WHO (2024) C_WHO

WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO. It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen... more

State of the Climate in Asia 2023
recommended

World Meteorological Organization (2024) CC

Asia remained the world’s most disaster-hit region from weather, climate and water-related hazards in 2023. Floods and storms caused the highest number of reported casualties and economic losses, whilst the impact of heatwaves became more severe, according to a new report from the World Meteorolog... more

HEARTS in the Americas. Compendium of essential clinical tools 2023

Pan American Health Organisation PAHO (2024) CC

Since 2016, the Pan American Health Organization (PAHO) has been promoting the implementation of the HEARTS Initiative in the Americas as a regional adaptation of the World Health Organization's Global HEARTS Initiative. During this time, 33 countries in the Region of the Americas have committed to ... more

Global alcohol action plan 2022-2030

World Health Organization WHO (2021) C_WHO

Alcohol use is deeply embedded in the social landscape of many societies, and some 2300 million people drink alcoholic beverages in most parts of the world. At the same time, more than half of the global population aged 15 years and older reported having abstained from drinking alcohol during the pr... more

2024 global AIDS report — The Urgency of Now: AIDS at a Crossroads

UNAIDS (2024) CC

This UNAIDS 2024 report brings together new data and case studies which demonstrate that the decisions and policy choices taken by world leaders this year will decide the fate of millions of lives and whether the world’s deadliest pandemic is overcome.

Rwanda Travel Advisory: Marburg Virus Disease Update

Rwanda Development Board (RDB) (2024) CC

October 2024

Global tuberculosis report 2024

World Health Organisation (WHO) (2024) C_WHO

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context... more

What is type 1 diabetes Poster

Diabetes Qualified, Diabetes nsw & act (2022) CC

Poster

SEAHEARTS Monitoring Framework

World Health Organisation (WHO) (2024) C_WHO

Monitoring Framework

Download (1618)

View PDF (2079)

Emergency Kits used by WHO

World Health Organization (2007)

Download (1771)

View PDF (3994)

Diagnostic atlas of intrathoracic tuberculosis in children

Robert Gie International Union Against Tuberculosis and Lung Disease (The Union) (2003)

A Guide for low income countries

Download (1037)

View PDF (1812)

Monthly village health nutrition day

Ministry of Health and Family Welfare Government of India (2007) C1

GUIDELINES FOR AWWs/ASHAs/ANMs/PRIs

Where women have no doctor

A. August Burns, Ronnie Lovich, Jane Maxwell, Katharine Shapiro Hesperian Health Guides (2020) CC

An essential resource that helps a community understand, treat, and prevent many health problems that affect women. Topics include reproductive health, violence, mental health, HIV, and more.